These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30014698)

  • 1. Nanocarbon-Based Glycoconjugates as Multivalent Inhibitors of Ebola Virus Infection.
    Rodríguez-Pérez L; Ramos-Soriano J; Pérez-Sánchez A; Illescas BM; Muñoz A; Luczkowiak J; Lasala F; Rojo J; Delgado R; Martín N
    J Am Chem Soc; 2018 Aug; 140(31):9891-9898. PubMed ID: 30014698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of giant globular multivalent glycofullerenes as potent inhibitors in a model of Ebola virus infection.
    Muñoz A; Sigwalt D; Illescas BM; Luczkowiak J; Rodríguez-Pérez L; Nierengarten I; Holler M; Remy JS; Buffet K; Vincent SP; Rojo J; Delgado R; Nierengarten JF; Martín N
    Nat Chem; 2016 Jan; 8(1):50-7. PubMed ID: 27055288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivalent Glycosylated Nanostructures To Inhibit Ebola Virus Infection.
    Illescas BM; Rojo J; Delgado R; Martín N
    J Am Chem Soc; 2017 May; 139(17):6018-6025. PubMed ID: 28394600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudosaccharide functionalized dendrimers as potent inhibitors of DC-SIGN dependent Ebola pseudotyped viral infection.
    Luczkowiak J; Sattin S; Sutkevičiūtė I; Reina JJ; Sánchez-Navarro M; Thépaut M; Martínez-Prats L; Daghetti A; Fieschi F; Delgado R; Bernardi A; Rojo J
    Bioconjug Chem; 2011 Jul; 22(7):1354-65. PubMed ID: 21650462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycofullerenes: Sweet fullerenes vanquish viruses.
    Vidal S
    Nat Chem; 2016 Jan; 8(1):4-6. PubMed ID: 26673255
    [No Abstract]   [Full Text] [Related]  

  • 6. Topological and Multivalent Effects in Glycofullerene Oligomers as EBOLA Virus Inhibitors.
    Ramos-Soriano J; Illescas BM; Pérez-Sánchez A; Sánchez-Bento R; Lasala F; Rojo J; Delgado R; Martín N
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of therapeutics for treatment of Ebola virus infection.
    Li H; Ying T; Yu F; Lu L; Jiang S
    Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of ebola virus infection.
    Picazo E; Giordanetto F
    Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
    Zhang T; Zhai M; Ji J; Zhang J; Tian Y; Liu X
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2364-2368. PubMed ID: 28462833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral infection: New tricks to treat Ebola.
    Cully M
    Nat Rev Drug Discov; 2016 Sep; 15(10):675. PubMed ID: 27681790
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of a broad-spectrum antiviral with activity against Ebola virus.
    Aman MJ; Kinch MS; Warfield K; Warren T; Yunus A; Enterlein S; Stavale E; Wang P; Chang S; Tang Q; Porter K; Goldblatt M; Bavari S
    Antiviral Res; 2009 Sep; 83(3):245-51. PubMed ID: 19523489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycofullerenes inhibit viral infection.
    Luczkowiak J; Muñoz A; Sánchez-Navarro M; Ribeiro-Viana R; Ginieis A; Illescas BM; Martín N; Delgado R; Rojo J
    Biomacromolecules; 2013 Feb; 14(2):431-7. PubMed ID: 23281578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir: a new medication for the Ebola virus disease pandemic.
    Nagata T; Lefor AK; Hasegawa M; Ishii M
    Disaster Med Public Health Prep; 2015 Feb; 9(1):79-81. PubMed ID: 25544306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease.
    Schafer A; Cheng H; Lee C; Du R; Han J; Perez J; Peet N; Manicassamy B; Rong L
    Curr Med Chem; 2018; 25(38):5177-5190. PubMed ID: 29032747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
    Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S
    Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The early clinical development of Ebola virus treatments.
    Bradfute SB
    Expert Opin Investig Drugs; 2017 Jan; 26(1):1-4. PubMed ID: 27838928
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report.
    Schibler M; Vetter P; Cherpillod P; Petty TJ; Cordey S; Vieille G; Yerly S; Siegrist CA; Samii K; Dayer JA; Docquier M; Zdobnov EM; Simpson AJH; Rees PSC; Sarria FB; Gasche Y; Chappuis F; Iten A; Pittet D; Pugin J; Kaiser L
    Lancet Infect Dis; 2015 Sep; 15(9):1034-1040. PubMed ID: 26201298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling Ebola virus dynamics: Implications for therapy.
    Martyushev A; Nakaoka S; Sato K; Noda T; Iwami S
    Antiviral Res; 2016 Nov; 135():62-73. PubMed ID: 27743917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-Year-Old Child with Severe Ebola Virus Disease: Laboratory-Guided Clinical Care in an Ebola Treatment Center in Guinea.
    Palich R; Gala JL; Petitjean F; Shepherd S; Peyrouset O; Abdoul BM; Kinda M; Danel C; Augier A; Anglaret X; Malvy D; Blackwell N;
    PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004393. PubMed ID: 27011342
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease?
    Almansa R; Eiros JM; Fedson D; Bermejo-Martin JF
    Lancet Glob Health; 2014 Dec; 2(12):e686. PubMed ID: 25433619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.